Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Effectiveness of Early-Line versus Late-Line Eribulin Treatment for Metastatic Breast Cancer
TCTR20250917001Not yet recruiting
- Sponsor
- N/A
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of eribulin in breast cancer (2 arms), sponsored by N/A. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on TCTR20250917001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250917001.